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TRANSPLANTATION
Age-adjusted recipient pretransplantation telomere length and treatment-related
mortality after hematopoietic stem cell transplantation
*Re´gis Peffault de Latour,1,2 *Rodrigo T. Calado,3,4 *Marc Busson,5 Jeffrey Abrams,3 Nadir Adoui,6 Marie Robin,1
Je´roˆme Larghero,7,8 Nathalie Dhedin,1 Alienor Xhaard,1 Emmanuel Clave,5 Dominique Charron,5,7 Antoine Toubert,5,7
Pascale Loiseau,5 †Ge´rard Socie´,1,2,8 and †Neal S. Young3
1Service d’He´matologie Greffe, Assistance Publique–Hoˆpitaux de Paris (AP-HP), Hoˆpital Saint Louis, Paris, France; 2Unite´ Inserm 728, Paris, France;
3Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD; 4Department of Internal Medicine, University of
Sa˜o Paulo at Ribeira˜o Preto Medical School, Ribeira˜o Preto, Brazil; 5Laboratoire d’ Immunologie et d’ Histocompatibilite´, AP-HP, Hoˆpital Saint Louis, Inserm
UMR 940, Institut Universitaire d’He´matologie, Hoˆpital Saint Louis, Paris, France; 6Laboratoire de Biochimie, AP-HP, Hoˆpital Saint Louis, Paris, France;
7Unite´ de The´rapie Cellulaire et CIC de Biothe´rapies, AP-HP, Hoˆpital Saint Louis, Paris, France; and 8Universite´ Paris-Diderot, Paris, France
Telomere attrition induces cell senes-
cence and apoptosis. We hypothesized
that age-adjusted pretransplantation telo-
mere length might predict treatment-
related mortality (TRM) after hematopoi-
etic stem cell transplantation (HSCT).
Between 2000 and 2005, 178 consecutive
patients underwent HSCT from HLA-
identical sibling donors after myeloabla-
tive conditioning regimens, mainly for
hematologic malignancies (n  153).
Blood lymphocytes’ telomere length was
measured by real-time quantitative PCR
before HSCT. Age-adjusted pretransplan-
tation telomere lengths were analyzed for
correlation with clinical outcomes. After
age adjustment, patients’ telomere-length
distribution was similar among all 4 quar-
tiles except for disease stage. There was
no correlation between telomere length
and engraftment, GVHD, or relapse. The
overall survival was 62% at 5 years (95%
confidence interval [CI], 54-70). After a
median follow-up of 51 months (range,
1-121 months), 43 patients died because
of TRM. The TRM rate inversely corre-
lated with telomere length. TRM in pa-
tients in the first (lowest telomere length)
quartile was significantly higher than in
patients with longer telomeres (P  .017).
In multivariate analysis, recipients’ age
(hazard ratio, 1.1; 95% CI, .0-1.1;
P  .0001) and age-adjusted telomere
length (hazard ratio, 0.4; 95% CI; 0.2-0.8;
P  .01) were independently associated
with TRM. In conclusion, age-adjusted
recipients’ telomere length is an indepen-
dent biologic marker of TRM after HSCT.
(Blood. 2012;120(16):3353-3359)
Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) is a
potentially curative procedure for many malignant and nonmalig-
nant hematologic blood disorders. However, transplantation re-
mains associated with a significant mortality rate because of
relapse and nonrelapse causes. Outcomes of HSCT have improved
over time, but treatment-related mortality (TRM) remains a major
concern. TRM is mainly associated with acute and chronic
graft-versus-host disease (GVHD), infections, interstitial pneumo-
nia, and toxicities of the HSCT procedure.1 Estimates of overall
survival (OS) and of TRM are of primary clinical importance in
weighing the risk/benefit ratio of allogeneic HSCT. Standard
factors, such as age, type, and stage of the underlying disease, as
well as pretransplantation comorbidities are not sufficient to
precisely predict transplantation tolerance and posttransplantation
survival.2 Some biomarkers, such as elevated pretransplantation
serum ferritin and C-reactive protein (CRP) levels, have been
suggested to be associated with an increased risk of morbidity and
mortality after HSCT.3-5
Telomeres are highly conserved protective terminal chromo-
somal structures consisting of hundreds to thousands of tandem
TTAGGG hexamers and their associated shelterin proteins. Telomeres
shorten with every mitotic cell division, and telomere attrition has a
fundamental role in cell senescence. The recent discovery that inherited
mutations in genes that encode for proteins that repair or protect
telomeres are etiologic in a range of human diseases has disclosed
clinical manifestations in diverse tissues, including the bone marrow,
lung, and liver, indicating that defects in telomere repair and protection
can cause organ failure.6 Dyskeratosis congenita (DC), an inherited type
of aplastic anemia, is caused by mutations in the telomerase complex
genes. HSCT is the only curative treatment for bone marrow failure in
patients with DC, but case reports and small series of patients have
suggested substantial risks of toxicity from radiation and chemotherapy,
as well as immune-related complications such as infections. As a result,
long-term survival of patients with DC after HSCT has been poor
because of TRM, including graft failure, GVHD, sepsis, pulmonary
fibrosis, cirrhosis, and veno-occlusive diseases.7,8
HSCT has been considered an experimental opportunity to
observe telomere dynamics in a highly proliferative cell environ-
ment. The telomere length of marrow cells from HSCT recipi-
ents was found considerably shorter than telomere length of
donor cells, likely reflecting an immediate increased replicative
demand after transplantation.9-11 That telomere attrition might
have a role in or serve as a marker of long-term outcome after
HSCT has been an attractive hypothesis, but data are limited (for
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a review, see Gadalla et al12). The potential impact of pretrans-
plantation telomere length on HSCT outcomes, notably TRM,
has not been reported.
We hypothesized that age-adjusted pretransplantation telo-
mere length might predict TRM after HSCT. To determine the
effects of telomere attrition on HSCT results, we measured
the pretreatment telomere length in 178 consecutive patients
who had undergone myeloablative HSCT from a matched
related donor, and we analyzed for correlations with outcomes
after HSCT.
Methods
Patients’ characteristics
All consecutive patients who underwent an HSCT after a standard
conditioning regimen13 at Saint Louis Hospital between January 2000 and
December 2005 and who received transplants from an HLA-identical
sibling donor were included in the study. GVHD prophylaxis consisted
of cyclosporine and methotrexate for all patients. Antithymocyte
globulin was administered to patients with nonmalignant diseases. A
total of 178 patients from whom sufficient samples were available for
testing were included in the analysis. Patients (or legal guardians)
signed informed consent according to approved protocols by the
Institutional Review Board of the Hospital Saint Louis. This study was
conducted in accordance with the Declaration of Helsinki. Patient and
disease characteristics are summarized in Table 1.
End point definitions
Neutrophil recovery was defined as the first of 3 consecutive days with a
neutrophil count of at least 0.5  109/L, and platelet recovery as the first
of 7 consecutive days with an unsupported platelet count of at least
20  109/L. Acute and chronic GVHD were diagnosed and graded
according to published criteria,14 with histopathologic confirmation
when possible. Disease risk was assessed according to the recent
European Leukemia Network classification15 concerning acute myeloid
leukemia (AML) in first complete remission. For acute lymphoid
leukemia (ALL), only patients with high-risk disease received trans-
plants in first complete remission, according to our local clinical trials
policy.16 Disease-stage categories were defined by ranking diseases
according to the number of previous (pretransplantation) treatments
received. Nonmalignant diseases were classified separately. Early stage
diseases included patients with malignant diseases who received
transplants in first complete remission as well as patients with chronic
myelogenous leukemia in chronic phase. Advanced-stage diseases
included malignant diseases transplanted beyond first complete remis-
sion as well as patients not in complete remission at time of HSCT.
Karnofsky performance status (KPS) was calculated in the 2 weeks before
begin the conditioning regimen. Serum ferritin and C-reactive protein
(CRP) levels were collected within the month and 2 weeks before the start
of the conditioning regimen, respectively.
Telomere-length measurement
Telomere length of pretreatment peripheral blood leukocytes was assessed
by quantitative PCR, as previously described,17 but with some modifica-
tions. Total leukocytes were separated by ammonium-based lysis of red
Table 1. Patient characteristics
Characteristics All
Telomere-length quartiles
1 2 3 4 P
Telomeres length, T:S mean 1.09 0.64 0.94 1.18 1.62 104
Age-adjusted telomeres length,
T:S mean (range)
0.16 (1.08 to 1.85) 0.61 (1.08 to0.42) 0.30 (0.42 to0.19) 0.08 (0.19 to 0.02) 0.35 (0.03 to 1.85) 104
Patients, no. (%) 178 45 (25) 44 (25) 45 (25) 44 (25)
Recipient sex, M/F 101/77 26/19 26/18 28/17 21/23 .55
Donor sex, M/F 95/83 24/21 27/17 23/22 21/23 .62
Mean age, y (SD) 31.8 32.4 33.3 30.7 30.8 .85
CMV recipient, Neg/Pos 63/114 17/28 18/26 15/29 13/31 .71
CMV donor, Neg/Pos 80/95 18/27 19/25 21/23 22/22 .78
Stem cell source, BM/PBSC 128/50 27/18 32/12 35/10 34/10 .21
Conditioning regimen*
TBI  12 Gy, no. (%) 67 17 (25) 15 (22) 19 (29) 16 (24) .82
BU-based regimen, no. (%)† 103 28 (27) 27 (26) 23 (23) 25 (24) .82
Malignant diseases, no. (%)‡
AML in CR1§ 46 17 (37) 7 (15) 8 (17) 14 (31) .11
Intermediate-I 20 7 (35) 5 (25) 4 (20) 4 (20) .36
Intermediate-II 9 3 (34) 0 2 (22) 4 (44) .36
Adverse 14 7 (50) 1 (11) 1 (11) 4 (28) .36
ALL in CR1 32 8 (25) 7 (22) 9 (28) 8 (25) .97
Chronic myelogenous leukemia 20 6 (30) 9 (45) 4 (20) 1 (5) .08
Myelodysplastic syndrome 13 5 (38) 3 (23) 2 (16) 3 (23) —
Disease stage, no. (%)
Nonmalignant 25 0 5 7 13 .002
Malignant early-stage 93 27 22 20 24 .002
Malignant advanced-stage 60 18 17 18 7 .002
T:S indicates telomere to single copy gene ratio; PBSC, peripheral blood stem cell; Neg, negative; Pos, positive; TBI, total body irradiation; BU, busulfan; AML, acute
myeloid leukemia; CR, complete remission; and ALL, acute lymphoid leukemia.
*Eight patients received cyclophosphamide in the context of severe aplastic anemia.
†Fifty patients received busulfan orally while 53 received it intravenously. The distribution as well as outcomes posttransplantation were not different among quartiles if the
busulfan was given orally or intravenously.
‡Twenty-two patients with acute leukemia did not receive transplants in first CR. Other malignant diseases included lymphoma (n  8), myeloproliferative disorders
different from CML (n  7), and myeloma (n  5).
§No patients with AML received transplants in CR1 in case of favorable risk.
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blood cells, and DNA was extracted using the DNeasy Blood kit (QIAGEN).
PCRs were performed in a Rotor Gene-Q (QIAGEN). Each sample was
assayed in triplicate and each reaction contained 1.6 ng of genomic DNA,
7.2 pg of each primer (except for single copy gene reverse primer that
contained 12 pg), and 16 L of Rotor-Gene SYBR Green PCR Master Mix
(QIAGEN). Each sample’s telomere length (x) was based on the telomere to
single copy gene ratio (T:S ratio) and based on the calculation of the Ct
[C
t(telomeres)/Ct(single gene)]. Telomere length was expressed as the relative T:S
ratio, which was normalized to the average T:S ratio of reference sample
[2(Ctx  Ctr)  2Ct], used for the standard curve, as reference sample, and
as validation sample. To compare results from different plate runs, the
results of each plate were approved only if the relative T/S ratio of the
validation reference sample fell within 3% variation. Laboratory personnel
conducting the telomere-length assay were blinded to patients’ clinical
outcomes before the statistical analysis.
Statistical methods
Age-adjusted telomere length for each subject was computed by subtracting
the subject’s linear predicted telomere length from the observed telomere
length. Quartiles of the age-adjusted telomere length were used to evaluate
the probabilities of engraftment, acute GVHD and cGVHD, TRM, relapse,
and overall survival. Summary statistics (means, proportions, and standard
deviations) stratified by age-adjusted telomere quartiles were used to
describe patients’ age, sex, and other baseline characteristics. P values
based on multisample tests for proportions and the analysis of variance tests
or Kruskall Wallis nonparametric tests were used to compare patients’
baseline characteristics. Kaplan-Meier analysis was used to calculate
survival rates. P values from the log-rank tests were used to evaluate the
overall covariate effects in the univariate analysis of OS. Univariate and
multivariate methods developed by Fine and Gray for competing risks
studies18 were used for assessment of prognostic factors of TRM with
relapse as a competing event. All tests were 2-sided, with type I error rate
fixed at 0.05. To improve the opportunity to discover unsuspected correla-
tions, we purposely did not adjust results for multiple comparisons.
Statistical analyses were performed with SPSS 19 software, Stata 11, and
R packages “cmprsk” (competing risks).
Results
Telomere length in patients before HSCT
Telomere lengths were measured in 178 recipients and in 173 healthy
HLA-identical sibling donors who served as controls (DNA was
missing for 5 individuals). Telomere lengths were shorter in
patients than in their sibling donors in all tested age brackets
(Figure 1). The median age of both recipients and donors was
comparable (31.8 [range, 3.4-64.8] and 31.6 years [range, 1.4-
66.8], respectively; P  .78). We then determined the age-adjusted
pretransplantation telomere length in patients’ samples; telomere
length was adjusted for age according to the telomere-length
attrition rate with aging in the donor control group. Because the
distribution of the telomere length was linear from 10 to 60 years of
age in controls, we thus determined the linear curve of telomere-
length distribution according to age (Figure 2; there were only few
patients younger than 10 or older than 60 years of age [n 17 and
4, respectively]). We categorized the patient population in quartiles
based on age-adjusted telomere length (Table 1). Patient character-
istics were similar among all 4 quartiles, except for disease stage
(with more advanced-stage malignant diseases in patients with
shortest telomeres [first quartile]).
Telomere length and outcomes after HSCT in the total population
The median follow-up of the study was 51 months (range,
1-121 months). All patients engrafted. The median time to achieve
absolute neutrophil count 500/L was 18 days (range, 4-45) and
median time to platelet count  20 000/L was 17 days (range,
7-58). Cumulative incidence of acute GVHD grade II-IV was 45%
(95% confidence interval (CI), 37-53) and chronic GVHD was 41%
at 36 months (95% CI, 33-49). Thirty-four patients relapsed,
leading to a cumulative incidence of 22% at 5 years (95CI
16%-28%). There was no correlation between telomere length and
engraftment, acute or chronic GVHD, or relapse (supplemental
Table 1, available on the Blood Web site; see the Supplemental
Materials link at the top of the online article).
Figure 1. Age bracket dot plot representation of telomere-length distribution
between donors (left) and recipients (right).
Figure 2. Linear curve representation of telomere-length distribution according
to the age.
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We have previously observed in patients with severe aplastic
anemia treated with immunosuppression a worse clinical outcome
in patients in the lowest quartile of telomere length.19 Here, we
adopted the same strategy for OS and TRM analysis. We separated
patients into 2 groups: shorter telomeres (first quartile) and longer
telomeres (upper 3 quartiles). The OS was 51% at 5 years in the
shorter (first) quartile in comparison to 65% in the longer quartiles
(2, 3, and 4; P  .07). During the study, 43 patients died because of
TRM. Causes of death are detailed in Table 2. As shown in Figure
3, TRM rate inversely correlated with telomere length. Patients
with shorter telomeres showed a statistically significant increased
TRM (P  .017). In multivariate analysis using competing risk
regression (including age-adjusted telomeres length, disease stage,
age, total body irradiation (TBI), and source of stem cells), age of
the recipients (HR, 1.1, 95% CI [1.0-1.1, P  .0001]) and age-
adjusted telomeres (HR, 0.4, 95% CI [0.2-0.8, P  .01]) were
independently associated with TRM (Table 3). KPS was not
included in the model because the majority of our patients were
scored  90% (148 of 161 with available KPS before transplanta-
tion). In addition, pretransplantation serum ferritin and CRP levels
were not associated with TRM in our population (supplemental
Figures 1 and 2, respectively) and thus not considered for
multivariate analysis. We also tested the potential role of donor
telomere length but did not found any correlation with outcomes
post-HSCT (Table 4).
Telomere length and outcomes after HSCT in patients with
malignant diseases
As patients with nonmalignant diseases usually have a better
outcome in comparison to patients with malignant diseases, we
performed an analysis restricted to the 153 patients with malignant
disorders. Again, a higher rate of TRM was observed for patients
who had shorter telomeres, especially for patients with advanced-
stage disease (supplemental Figure 3). In multivariate analysis, the
same 2 independent factors (age and age-adjusted telomere length)
were present when analysis was restricted to the patients in the
malignant disease group (n 153; respectively, P  .0004, HR 1.1
and P  .018, HR 0.43). We also included the disease risk as stated
in Table 1 in the model (AML CR1 intermediate risk, AML CR1
adverse risk, ALL CR1 and other diseases). Age and age-adjusted
telomere length remained the only 2 factors associated with TRM
(respectively, P  .001, HR 1.1 and P  .018, HR 0.42). As shown
in Figure 4, telomere length predicted TRM in all disease-risk
subgroups except for intermediate-risk AML where the TRM was
low.
Discussion
To our knowledge, this is the first study to evaluate the impact of
leukocyte pretransplantation telomere length on TRM in the
context of HSCT. Accelerated telomere shortening has been
reported to occur after allogeneic HSCT.10,11,20 Telomere attrition
has mainly been observed during the first year after allogeneic
HSCT; thereafter, telomere-length dynamics of recipients appear
not to differ from those of their donors.21-23 Chronic GVHD and a
female donor were associated with greater differences in telomere
length between donor and recipient after HSCT.24 Here, we found
that shorter leukocyte pretransplantation telomere length correlated
with higher TRM posttransplantation.
Genetic predisposition (telomerase gene mutations), environmen-
tal factors (reactive oxidative stress), and iatrogenic interventions
(chemotoxic drugs and radiation) all may accelerate telomere loss.
In our patients, in the shortest quartile of telomere length, there
may be unidentified genetic lesions relating to telomere repair or
structure, or they may have inherited shorter telomeres from their
parents. However, genetic predisposition is reliably predicted by
extremely short telomere length, and our patients’ values were
within the normal range. The influence of chemotherapy on
telomere length has been demonstrated in breast cancer patients
after multiple chemotherapy courses25 and in lymphoma patients
undergoing high-dose chemotherapy courses.26 Accelerated telo-
mere shortening has also been observed after autologous HSCT and
appears to persist.27-29 Telomere shortening may be related to
pretransplantation exposure to multiple courses of chemotherapy in
our population, as suggested by the association of advanced-stage
disease and shorter telomere length. It seems unlikely that telomere
length could have been influenced by circulating blast cells because
no patients with refractory acute leukemia were included and
patients with other refractory diseases need to be sensitive to
chemotherapy before HSCT with usually no malignant circulating
Table 3. Competing risk regression (Fine and Gray) for treatment-
related mortality
Risk factor HR (95% CI) P
Age-adjusted telomere length 0.4 (0.2-0.8) 102
Age per year 1.1 (1.0-1.1) 104
Source of stem cells 0.8 (0.3-1.8) .61
TBI in the conditioning regimen 0.8 (0.4-1.5) . 5
Severity of the disease 1.6 (0.9-3.1) .14
HR indicates hazard ratio; CI, confidence interval; and TBI, total body irradiation.
Table 2. Causes of death due to the transplantation procedure
Causes of death
Telomere length
All patients,
N  178,
no. (%)
Q1,
N  45,
no. (%)
Q2, Q3, and Q4,
N  133,
no. (%) P
GVHD 13 (7.3) 5 (11) 8 (6) .32
Infections 12 (6.7) 5 (11) 7 (5) .18
Toxicity 2 (1) 0 2 (1.5) 1
Poor graft function 1 (0.5) 0 1 (0.8)
Hemorrhage 1 (0.5) 0 1 (0.8)
Multiple organ failure 8 (4.4) 4 (9) 4 (3) .11
Interstitial pneumonitis 1 (0.5) 1 (2) 0
ARDS 1 (0.5) 1 (2) 1 (0.8)
Other 4 (2) 1 (2) 3 (2.3) 1
Q indicates quartile; and ARDS, acute respiratory distress syndrome.
Figure 3. Telomere-length and treatment-related mortality cumulative inci-
dences in the overall population.
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cells at time of transplantation. Nevertheless, in the current study,
short telomere length was a survival risk factor independent of
disease stage, the latter including by definition the number of
previous chemotherapy cycles (first or second remission).
As accelerated telomere loss postautologous HSCT has been
implicated as a predictor for the development of therapy-related
myelodysplasia and acute myeloid leukemia,30 this independent
association between short telomeres and TRM may be pathophysi-
ologic, not simply a biomarker. Patients rated as advanced stage by
disease, prior relapses, and remission, or who have equivalent
records of chemotherapy or radiation may not have equivalent
functional consequences to these exposures, for reasons ranging
from variations in medical practice to differences in drug metabo-
lism pathways. Cumulative damage to DNA may be better reflected
by telomere length than by simple medical history or complex
genomic analysis. Causes of death were equally distributed in the
first quartile compared with the other 3 quartiles, consistent with a
nonorgan specific but general phenomenon. We observed the same
number of deaths (n 4) from multiorgan failure in the first
quartiles in comparison with the other 3 quartiles, in favor of this
hypothesis. Telomere length could thus reflect accelerated “physi-
ologic” aging in our population. A previous study evaluated the
cost, in terms of telomere loss, of delivering high-dose cytarabine
corresponded to that normally paid in approximately 20 years of
life in the absence of nonphysiologic hematopoietic stress.26 In our
population, we found shorter telomere lengths in recipients in all
tested age brackets, especially after 30 years old, more or less the
age limit where the intensity of the conditioning regimen (reduced
vs standard) is regularly discussed. However, recipients’hematopoi-
etic cells were chosen for analysis as a surrogate for telomere
length in other affected tissues and may not directly reflect the
telomere length in affected organs. Nevertheless, a good correlation
of telomere length in leukocytes, buccal mucosa swab, and
fibroblasts has been demonstrated,31 suggesting that the telomere
length in peripheral blood leukocytes may reflect the length of
telomeres in other tissues.
A conventional high-dose transplantation preparative regimen
causes serious toxicity to organs such as the gut, liver, kidneys,
heart, and lungs.2 Reduced-intensity or nonmyeloablative condition-
ing regimens have relied on graft-versus-tumor effects for disease
control, and their advent has allowed relatively older and more
severely ill patients to be offered allogeneic HSCT. It has become
increasingly important to optimize pretransplantation risk assess-
ment to improve HSCT decision-making and clinical trial assign-
ments. Chronologic age has been long used as the main HSCT
prognostic variable as exclusion criteria for high-dose conditioning
regimen, but age alone is a poor predictor of HSCT outcome32; in
some studies there has been little impact of chronologic age on
allogeneic HSCT outcomes.33,34 Recent efforts have resulted in the
advent of a weighted scoring system that could sensitively capture
multiple-organ comorbidities before HCT. Those studies assess not
only biologic aging composed of chronologic age but also physical
function and organ comorbidities (for a review, see Sorror et al2).
However, our population was mainly composed of young patients
with no comorbidities and in good physical status (KPS 90%)
for which previously described biomarkers (pretransplantation
serum ferritin and CRP levels) were not useful. If our results are
independently confirmed, pretransplantation telomere length might
be a new biomarker helpful for physicians to choose among
treatment options, as, for example, the choice of conditioning
Table 4. Donor age-adjusted telomere length and outcomes after HSCT in the total population
Characteristics All patients
Telomere-length quartiles
PQ1,< 0.17 Q2,0.26 to 0 Q3, 0 to 0.16 Q4,> 0.16
Neutrophils,> 500/L .36
No. 162 40 41 40 41
Mean, d 19.6 19.3 19.3 20.2 19.6
95% CI 18.6-20.6 17.7-21 17.7-21.4 17.8-22.6 17.6-21.7
Platelets,> 20 000/L .95
No. 148 35 39 38 36
Mean, d 19 18.4 18.1 18.8 20.8
95% CI 17.7-20.3 15.8-20.1 15.2-21 16.2-21.3 18-23.6
Acute GVHD .17
No. 178 40 43 42 43
CI at 100 d 0.45 0.45 0.47 0.29 0.51
95% CI .37-.53 .31-.62 .33-.62 .17-.45 .37-.67
Chronic GVHD .25
No. 161 40 39 41 41
CI at 24 mo 0.41 0.49 0.53 0.32 0.46
95% CI .34-.50 .34-.66 .38-.70 .20-.49 .32-.63
Relapse .47
No. 147 36 37 40 34
CI at 50 mo 0.21 0.25 0.23 0.17 0.23
95% CI .15-.27 .12-.45 .12-.43 .08-.33 .12-.42
TRM .15
No. 178 43 43 43 43
CI at 50 mo 0.24 0.26 0.30 0.14 0.14
95% CI .17-.31 .12-.40 .12-.45 0-.29 .03-.25
Survival .07
No. 178 43 43 43 43
CI at 50 mo 0.64 0.63 0.49 0.77 0.69
95% CI .57-.72 .46-.75 .33-.62 .61-.87 .53-.81
Q indicates quartile; CI, confidence interval; and TRM, treatment-related mortality.
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regimen. Pretransplantation telomere length is thus able to predict
TRM in a population where the common predictors (except
chronologic age, also found as an independent-associated factor)
are not helpful and might identify patients more likely to benefit
from reduced-intensity conditioning.
Recipient pretransplantation telomere length was not associated
either with engraftment or GVHD. Telomere length is a biologic
marker of replicative history and predicts remaining proliferative
capacity in vitro.35 Extensive telomere shortening is reported to be
involved in late graft failure post-HSCT.36 None of our patients
experienced engraftment failure. Graft failure is mainly due to
immunization pre-HSCT or an unrelated source of stem cells
(notably umbilical cord blood), circumstances that were excluded
from the current work. Telomere length did not appear to be critical
for hematopoietic recovery, perhaps explained in part by the
clinical transplantation setting, as only matched related sibling
transplantations were evaluated. In our population of patients
receiving HLA-identical grafts, genetic differences in minor histo-
compatibility antigens triggered GVHD. Donor T cells are respon-
sible for GVHD and recognized minor HA initially presented by
recipient-derived dendritic cells.37 Previous experimental studies
have demonstrated that increased risk of GVHD in older patients is
linked to older dendritic cells. We also did not find any correlation
between donor telomere length and outcomes post-HSCT. Our
donor population is relatively homogeneous, mainly young healthy
subjects who are HLA-identical to recipient patients, and it was not
unexpected that donor telomere length would not be predictive of
outcomes.
Our work has strengths and limitations. The strengths include
the homogeneous cohort prospectively enrolled in our center over a
short period of time, and specified diagnostic criteria, homoge-
neous conditioning regimen, GVHD prophylaxis, supportive care,
and prospectively determined and defined clinical outcomes. We
monitor our patients indefinitely at specified intervals, and our
policy requires periodic assessment for adverse events like relapse
and late toxicity. Our study is limited because of the retrospective
nature of the analysis and the relatively small number of patients,
which did not allow for validation testing in a separate cohort or for
reliable subgroup analysis. As a research facility and referral
center, our patient population also may not be representative and
our results not necessarily generalizable. Therefore, our results
need to be replicated to validate the observed associations and to
determine reliable telomere-length thresholds that could be incorpo-
rated in treatment algorithms.
In conclusion, age-adjusted recipient pretransplantation telo-
mere length was identified as an independent biologic marker of
TRM after HSCT from related donors using a myeloablative
conditioning regimen. Prediction of important disease-related
complications is critical to risk stratification and patient manage-
ment. Pre-HSCT telomeres length thus appear as a new predictor of
TRM that need to be confirmed on independent cohort of patients
and on other HSCT setting.
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Figure 4. Telomere-length and TRM cumulative incidences according to the
disease risk in patients with malignant diseases.
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